Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline

Core Insights - Moderna reported a loss of $2.50 per share in Q4 2024, which is an improvement compared to the Zacks Consensus Estimate of a loss of $2.69 and a significant decline from earnings of 55 cents per share in the same period last year [1][2] - Total revenues for Q4 were $966 million, exceeding the Zacks Consensus Estimate of $956 million, but reflecting a year-over-year decline of approximately 64.3% due to lower product sales [2][3] - The company's stock has decreased by 65% over the past year, contrasting with a 3.6% decline in the industry [2] Financial Performance - Product sales fell by 66.4% year-over-year to $938 million, primarily due to a significant drop in Spikevax sales [3][4] - Spikevax sales amounted to $923 million in Q4 2024, down from $2.8 billion in the previous year, attributed to the earlier launch of an updated COVID-19 vaccine [4] - Sales from the recently launched RSV vaccine, mResvia, were minimal at $15 million, with management expecting low sales in the quarter [5][9] - Total revenues for 2024 were $3.2 billion, marking a 52.9% decline year-over-year, with a reported loss of $9.28 per share, an improvement from a loss of $12.33 per share in the prior year [11] Future Guidance - For 2025, Moderna expects total revenues between $1.5 billion and $2.5 billion, primarily from COVID-19 and RSV vaccine sales, with a Zacks Consensus Estimate of $2.30 billion [12] - The company anticipates R&D expenses of around $4.1 billion and SG&A expenses of approximately $1.1 billion for 2025 [13] Pipeline Developments - Moderna submitted three regulatory filings to the FDA in Q4 2024, including for mRNA-1283 (next-generation COVID-19 vaccine) and mRNA-1083 (COVID-19 and influenza combination vaccine), with decisions expected in 2025 [14][15] - The company is also advancing over 40 mRNA-based investigational candidates, including those targeting cancer, with several in late-stage studies [17][18] - A registrational study for mRNA-3705, a therapeutic candidate for methylmalonic acidemia, is planned for later in 2025 [19]